# Hepatorenal Syndrome

Hepatorenal syndrome–acute kidney injury is a time-sensitive, exclusionary diagnosis in decompensated cirrhosis. Rapidly identify infection, hypovolemia, acute tubular injury, obstruction, and venous congestion before selecting albumin plus vasoconstrictor therapy and pursuing liver transplantation.

**Clinical question:** How should physicians diagnose, phenotype, and treat hepatorenal syndrome–acute kidney injury in patients with cirrhosis?

Updated: 2026-08-24T17:27:04.962091+00:00

## What matters in practice
- In cirrhosis with ascites, AKI is a serum creatinine increase of at least 0.3 mg/dL within 48 hours or at least 50% within 7 days; HRS-AKI is considered only after hypovolemia, shock, nephrotoxins, and structural kidney disease are excluded. [22][24]
- Treat reversible precipitants immediately, particularly infection, gastrointestinal fluid loss, overdiuresis, nephrotoxin exposure, and post-paracentesis circulatory dysfunction; do not delay etiologic evaluation while awaiting an albumin response. [11][14][24]
- Urinary NGAL, IL-18, KIM-1, and L-FABP are higher in acute tubular necrosis than in functional AKI phenotypes and can support a structural injury branch when standard clinical assessment is indeterminate. [10][12][13]
- Terlipressin is FDA-approved to improve kidney function in adults with HRS and rapidly declining kidney function, but requires baseline and continuous oxygen-saturation monitoring and discontinuation for SpO2 below 90% or worsening hypoxia. [1]
- Avoid terlipressin in ACLF grade 3 and use particular caution with volume overload, because respiratory failure and ischemia can jeopardize liver-transplant eligibility. [1][20]
- Liver transplantation is the definitive treatment pathway; vasoconstrictor therapy is principally a bridge while renal function and transplant candidacy are reassessed. [20][21]

## Recognize AKI and address immediately reversible threats

Manage AKI in decompensated cirrhosis as a diagnostic emergency rather than presuming HRS.

Use an AKI threshold of serum creatinine increase of at least 0.3 mg/dL within 48 hours or at least 50% from baseline within 7 days. AKI occurs in approximately 27% to 53% of hospitalized patients with cirrhosis and ascites; prerenal azotemia and acute tubular necrosis are the most common etiologies. [22][24]

At presentation, identify and reverse hemodynamic or nephrotoxic triggers: shock, infection, gastrointestinal hemorrhage or fluid loss, excess diuresis, nephrotoxic exposure, and recent large-volume paracentesis without appropriate albumin replacement. HRS-AKI should not be assigned until hypovolemia or shock, nephrotoxins, intrinsic kidney disease, and obstructive disease have been actively excluded. [14][22][24]

Obtain urinalysis with urine microscopy, urine protein assessment, and renal ultrasonography while evaluating volume status and infection. Hematuria, pyuria, substantial proteinuria, casts suggestive of tubular injury, or urinary obstruction should redirect management toward intrinsic or postrenal AKI rather than a purely functional HRS phenotype. [11][14][17]

Use point-of-care ultrasound as an adjunct when physical examination and routine laboratory indices do not resolve volume status. In one reported cohort, 62% of patients clinically labeled HRS had high cardiac filling pressures on right-heart catheterization and improved creatinine after volume expansion was stopped and diuretics were started; congestive physiology should therefore prevent reflexive albumin escalation. [16]
- Measure serial serum creatinine and assess urine output during the initial evaluation; a rising creatinine despite correction of an identified precipitant increases concern for HRS-AKI or acute tubular injury. [11][15]
- Perform diagnostic evaluation for infection early, especially spontaneous bacterial peritonitis, because infection is a common setting for HRS-AKI and may coexist with other renal insults. [14][24]
- For spontaneous bacterial peritonitis with increased or rising creatinine, administer albumin 1.5 g/kg within 6 hours of diagnosis, then 1 g/kg on day 3. [2]

*Initial etiologic branches for AKI in cirrhosis and the management consequence. [10][11][14][16][24]*

| AKI branch | Findings that shift probability | Immediate next action |
| --- | --- | --- |
| Hypovolemic prerenal AKI | Volume loss, gastrointestinal bleeding, overdiuresis, or another reversible reduction in effective circulating volume; renal function improves after correction. [11][14] | Correct the precipitant and reassess creatinine response before labeling HRS-AKI. [11][14] |
| HRS-AKI | Cirrhosis with ascites and prerenal AKI after exclusion of shock, nephrotoxins, structural renal disease, and obstruction; no standalone diagnostic test confirms HRS. [13][17][24] | Use albumin-based volume assessment and initiate a vasoconstrictor strategy when the functional phenotype persists. [11][20] |
| Acute tubular injury or necrosis | Urine injury biomarkers including NGAL, IL-18, KIM-1, and L-FABP are higher than in HRS or prerenal azotemia; tubular injury may coexist with hemodynamic AKI. [10][12][4] | Treat the underlying tubular insult and avoid assuming response to HRS-directed vasoconstriction. [10][13] |
| Venous congestion or cardiorenal physiology | POCUS or invasive hemodynamics demonstrate high filling pressures; creatinine may improve when albumin is stopped and diuresis is initiated. [16] | Avoid indiscriminate volume expansion; tailor diuretic and fluid management to congestion. [16] |
| Postrenal or glomerular disease | Hydronephrosis on ultrasonography, or active urine sediment and proteinuria suggesting structural renal disease. [11][14] | Treat obstruction or pursue nephrology-directed intrinsic renal evaluation rather than HRS-only therapy. [11][14] |

## Establish HRS-AKI only after competing renal phenotypes are addressed

HRS-AKI is an exclusionary clinical syndrome in advanced cirrhosis, not a urine sodium or creatinine threshold diagnosis.

Current AKI-era terminology replaces HRS type 1 with HRS-AKI and recognizes HRS-NAKI for the former type 2 phenotype. HRS-AKI occurs in advanced cirrhosis with portal-hypertensive vasodilation and inflammatory activation, but the clinical diagnosis remains dependent on excluding prerenal, intrinsic, and obstructive causes. [17][4][13]

Do not wait for an arbitrary creatinine concentration before acting. AKI-based HRS criteria were designed to identify clinically meaningful renal deterioration earlier than historical creatinine-threshold definitions, and earlier terlipressin initiation at lower creatinine has been associated with greater treatment effectiveness. [15][20]

A conventional approach is to withhold obvious precipitants and give intravenous albumin-based volume expansion for up to 48 hours before designating HRS-AKI. This remains a useful diagnostic maneuver when hypovolemia is plausible, but it must be balanced against pulmonary edema and venous congestion, especially when ultrasound suggests high filling pressures. [11][16]

Interpret urine indices cautiously. Fractional excretion of sodium and urine sodium are included among tools used to phenotype AKI in cirrhosis, but structural biomarkers may add greater discrimination when acute tubular injury remains a serious alternative. Urinary NGAL, IL-18, KIM-1, and L-FABP were significantly higher in adjudicated acute tubular necrosis than in other AKI etiologies in cirrhosis. [10][11][12]
- Favors a functional HRS-AKI pathway: cirrhosis with ascites, persistent prerenal physiology after correction of reversible causes, and no convincing evidence of structural renal injury or obstruction. [14][17][24]
- Favors acute tubular injury: a compatible ischemic, septic, toxic, or inflammatory insult plus elevated structural urine injury biomarkers. [4][10][12]
- Favors a mixed phenotype: severe infection, ACLF, bile-acid or endotoxin-mediated injury, or prolonged renal hypoperfusion; functional and structural mechanisms can coexist. [4][8][9]
- Escalate to hepatology and nephrology when active urinary sediment, proteinuria, obstructive findings, unresolved volume status, or failure of an initially plausible HRS-directed strategy makes the phenotype uncertain. [11][14][16]

*Tests that refine the HRS-AKI differential when clinical examination alone is insufficient. [10][11][16]*

| Test | Interpretation | Decision consequence |
| --- | --- | --- |
| Urinalysis and microscopy | Red or white blood cells, casts, or other active sediment support a structural or infectious renal process rather than uncomplicated functional HRS. [11] | Investigate intrinsic renal disease or infection and do not rely on vasoconstrictor therapy alone. [11][14] |
| Urine protein assessment | Proteinuria increases concern for structural kidney disease. [11][14] | Obtain nephrology input and consider disease-specific evaluation. [11][14] |
| Renal ultrasonography | Hydronephrosis or other obstruction excludes a pure HRS-AKI explanation. [11][14] | Relieve or otherwise manage obstruction. [14] |
| Urinary NGAL, IL-18, KIM-1, L-FABP | Higher concentrations support acute tubular necrosis over HRS or prerenal azotemia. [10][12] | Prioritize tubular-injury management and reassess expected benefit of HRS-directed vasoconstriction. [10][13] |
| POCUS assessment of congestion | High filling pressures may identify albumin-intolerant venous congestion despite a clinical HRS label. [16] | Stop further volume expansion and consider diuresis when congestion is demonstrated. [16] |

## Use albumin and vasoconstrictors selectively for persistent HRS-AKI

Treatment aims to reverse functional renal vasoconstriction while avoiding respiratory and ischemic complications.

For patients meeting a persistent HRS-AKI phenotype after correction of reversible causes, combine vasoconstrictor therapy with albumin-based management. Vasoconstrictors including terlipressin, norepinephrine, and midodrine plus octreotide act on the splanchnic circulation to improve renal function; terlipressin has the strongest evidence base and is more effective than albumin alone for HRS kidney-injury reversal. [20][21]

In the United States, terlipressin is FDA-approved to improve kidney function in adults with HRS accompanied by rapid reduction in kidney function. The FDA label states that patients with serum creatinine above 5 mg/dL are unlikely to benefit, making delayed initiation a poor-value strategy when the diagnosis is established. [1]

Terlipressin requires respiratory-risk stratification before the first dose. Obtain baseline SpO2, monitor continuously by pulse oximetry during therapy, and discontinue terlipressin if SpO2 falls below 90% or if hypoxia or respiratory symptoms develop. Fluid overload increases respiratory-failure risk; reduce or discontinue albumin and other fluids and use diuretics judiciously until volume status improves. [1]

Avoid terlipressin in ACLF grade 3 because of substantial respiratory-failure risk. Also assess for ischemic risk and transplant implications: terlipressin-related respiratory failure or ischemia can render a listed patient ineligible for transplantation, so a patient with worsening oxygenation or volume overload should have treatment interrupted rather than continued solely to pursue creatinine improvement. [1][20]

Norepinephrine plus albumin is an alternative vasoconstrictor strategy, particularly where close hemodynamic monitoring is available. Midodrine plus octreotide is used off label in the United States but is less effective than terlipressin in comparative evidence and should not be considered equivalent therapy when terlipressin is appropriate and available. [20][21]
- Before terlipressin: document baseline SpO2, assess respiratory symptoms and volume status, and identify ACLF grade 3 as a major safety exclusion. [1]
- During terlipressin: use continuous pulse oximetry and regular clinical respiratory assessments; stop therapy for SpO2 below 90%, hypoxia, or worsening respiratory symptoms. [1]
- With fluid overload: reduce or stop albumin and other fluids, use diuretics judiciously, and temporarily interrupt, reduce, or discontinue terlipressin until volume status improves. [1]
- With serum creatinine above 5 mg/dL: reassess expected benefit, as FDA labeling identifies these patients as unlikely to benefit from terlipressin. [1]

*Vasoconstrictor selection and safety considerations in HRS-AKI. [1][20][21]*

| Strategy | Role | Key constraint |
| --- | --- | --- |
| Terlipressin plus albumin | FDA-approved therapy to improve kidney function in adults with HRS and rapidly declining kidney function; most effective medical option described for HRS-AKI reversal. [1][20] | Continuous SpO2 monitoring; discontinue for SpO2 below 90% or hypoxia; avoid ACLF grade 3; benefit is unlikely when creatinine exceeds 5 mg/dL. [1] |
| Norepinephrine plus albumin | Alternative vasoconstrictor approach with efficacy similar to or potentially lower than terlipressin in head-to-head evidence. [20][21] | Requires a setting capable of close hemodynamic monitoring. [20] |
| Midodrine plus octreotide plus albumin | Off-label U.S. approach sometimes used outside intensive monitoring settings. [20][21] | Inferior efficacy to terlipressin; do not substitute when a patient is eligible for terlipressin. [20] |

## Prevent paracentesis- and infection-associated renal deterioration

Albumin use is indication-specific; excessive administration can worsen congestion and terlipressin-associated respiratory risk.

After paracentesis exceeding 5 L, infuse 20% or 25% albumin at 8 g per liter of ascites removed. For paracentesis below 5 L, the same dose can be considered in ACLF or in patients at high risk for post-paracentesis AKI. [2][3]

In spontaneous bacterial peritonitis with increased or rising serum creatinine, administer albumin 1.5 g/kg within 6 hours of diagnosis and 1 g/kg on day 3. This is a renal-protective adjunct to infection management and should occur before persistent renal dysfunction is attributed solely to HRS-AKI. [2]

For refractory ascites, consider transjugular intrahepatic portosystemic shunt in appropriately selected patients. In contrast, automated low-flow ascites pumps should be restricted to special circumstances with robust clinical governance, audit, or research arrangements because survival benefit has not been demonstrated. [2][3]
- Large-volume paracentesis greater than 5 L: albumin 8 g/L removed after completion. [3]
- Paracentesis below 5 L with ACLF or high post-paracentesis AKI risk: consider albumin 8 g/L removed. [2]
- SBP plus increased or rising creatinine: albumin 1.5 g/kg within 6 hours, then 1 g/kg on day 3. [2]
- Refractory ascites: evaluate candidacy for TIPS rather than repeated escalation of unsupported device-based drainage strategies. [2][3]

*Albumin indications relevant to AKI and HRS risk in cirrhosis. [2][3]*

| Clinical setting | Albumin regimen | Decision point |
| --- | --- | --- |
| Paracentesis greater than 5 L | 20% or 25% albumin, 8 g/L of ascites removed after the procedure. [3] | Use routinely to reduce post-paracentesis circulatory and renal risk. [3] |
| Paracentesis below 5 L with ACLF or high AKI risk | Consider 20% or 25% albumin, 8 g/L removed. [2] | Individualize because recommendation strength and evidence certainty are lower. [2] |
| SBP with increased or rising creatinine | 1.5 g/kg within 6 hours of diagnosis, then 1 g/kg on day 3. [2] | Administer promptly as part of infection-associated renal dysfunction management. [2] |
| Suspected HRS-AKI with congestion | Do not automatically escalate albumin; reduce or stop albumin and other fluids when volume overload is present. [1][16] | Protect oxygenation and reassess the hemodynamic phenotype. [1][16] |

## Treat HRS-AKI as a liver-transplant urgency and monitor for treatment harm

Renal reversal is clinically valuable, but definitive management depends on liver-transplant assessment.

Initiate or expedite liver-transplant evaluation when HRS-AKI is identified. Liver transplantation is the definitive treatment for HRS-AKI and other advanced cirrhosis complications; terlipressin-based treatment is commonly used as a bridge while transplant candidacy, renal trajectory, and need for renal replacement therapy are reassessed. [20][21]

Follow serum creatinine trajectory, oxygenation, respiratory examination, and volume status during vasoconstrictor therapy. A fall in creatinine supports response, whereas progressive AKI should prompt renewed evaluation for acute tubular injury, occult infection, persistent hypovolemia, venous congestion, or another unrecognized structural process rather than automatic continuation of an ineffective HRS-directed course. [10][11][16]

Respond to terlipressin toxicity immediately. Discontinue the drug for SpO2 below 90%; interrupt, reduce, or discontinue treatment during volume overload until improvement; and reassess for ischemic complications. These events matter both for short-term safety and because respiratory failure or ischemia may affect transplant eligibility. [1]

Renal replacement therapy may be needed for selected patients with severe renal dysfunction as a bridge in the transplant pathway. Terlipressin treatment has been associated with less renal replacement therapy use and better post-transplant kidney function in reported analyses, but it does not replace definitive transplant planning. [20][21]
- Monitor oxygenation continuously during terlipressin treatment and stop therapy for SpO2 below 90%. [1]
- Reassess volume status repeatedly; new edema, pulmonary symptoms, or ultrasound evidence of congestion should trigger reduction of fluids and reconsideration of albumin exposure. [1][16]
- If creatinine fails to improve, revisit the AKI phenotype with urine microscopy, structural injury biomarkers when available, renal imaging, infection assessment, and hemodynamic evaluation. [10][11][14][16]
- Coordinate transplant evaluation early because a serious terlipressin adverse event can compromise eligibility. [1][20]

*Monitoring triggers that should change HRS-AKI management. [1][10][11][16][20]*

| Monitoring finding | Interpretation | Action |
| --- | --- | --- |
| SpO2 below 90% during terlipressin | Terlipressin-associated hypoxia risk. [1] | Discontinue terlipressin. [1] |
| New fluid overload or worsening respiratory symptoms | Higher risk for respiratory failure during terlipressin and albumin exposure. [1] | Reduce or stop albumin and other fluids, use diuretics judiciously, and interrupt or modify terlipressin until volume status improves. [1] |
| Persistent or worsening creatinine despite presumed HRS therapy | May represent acute tubular injury, mixed injury, persistent infection, occult hypovolemia, or congestion. [4][10][16] | Repeat etiologic assessment rather than assuming refractory functional HRS alone. [10][11][16] |
| Creatinine above 5 mg/dL before terlipressin | Low likelihood of benefit according to FDA labeling. [1] | Reassess treatment value and prioritize transplant-pathway planning and supportive renal management. [1][20] |

## References
1. 022231Orig1s000 - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022231Orig1s000lbl.pdf
2. Guidelines on the management of ascites in cirrhosis - Gut — gut.bmj.com — https://gut.bmj.com/content/70/1/9
3. Guidelines on the management of ascites in cirrhosis — gut.bmj.com — https://gut.bmj.com/content/gutjnl/early/2020/10/15/gutjnl-2020-321790.full.pdf
4. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis | Nature Reviews Nephrology — www.nature.com — https://www.nature.com/articles/s41581-019-0218-4
5. Management of hepatorenal syndrome in patients with cirrhosis | Nature Reviews Nephrology — www.nature.com — https://www.nature.com/articles/nrneph.2011.96
6. Cardio-Pulmonary-Renal Interactions: A Multidisciplinary Approach — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2015.04.024
7. Advances in the management of complications from cirrhosis — academic.oup.com — https://academic.oup.com/gastro/article/doi/10.1093/gastro/goae072/7727525
8. Hepatorenal syndrome in acute-on-chronic liver failure with acute ... — academic.oup.com — https://academic.oup.com/gastro/article-pdf/9/6/505/41794381/goab040.pdf
9. Hepatorenal syndrome in acute-on-chronic liver failure with ... — academic.oup.com — https://academic.oup.com/gastro/article/9/6/505/6375168
10. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury - Belcher - 2014 - Hepatology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/hep.26980
11. Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment... : Kidney360 — journals.lww.com — https://journals.lww.com/kidney360/fulltext/2022/02000/hepatorenal_syndrome_type_1__from_diagnosis.26.aspx
12. Kidney biomarkers and differential diagnosis of patients ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.26980
13. Hepatorenal Syndrome Type 1: Diagnosis and Treatment — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2949813923000575
14. Hepatorenal Syndrome–Acute Kidney Injury in Liver Transplantation — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1542356523004949
15. Hepatorenal syndrome in the era of acute kidney injury - Solé — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/liv.13893
16. Acute kidney injury and point-of-care ultrasound in liver cirrhosis: redefining hepatorenal syndrome | Clinical Kidney Journal | Oxford Academic — academic.oup.com — https://academic.oup.com/ckj/article/17/5/sfae112/7646085
17. Renal damage in Hepatorenal Syndrome: A still unsolved issue - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2210740123001031
18. Ascites, Renal Dysfunction and Hepatorenal Syndrome — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/hep.27493
19. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0272638621008908
20. Use of Terlipressin in AKI Associated with Hepatorenal... : Kidney360 — journals.lww.com — https://journals.lww.com/kidney360/fulltext/2024/06000/use_of_terlipressin_in_aki_associated_with.5.aspx
21. Safety and efficacy of continuous terlipressin... : Liver Transplantation — journals.lww.com — https://journals.lww.com/lt/fulltext/2024/10000/safety_and_efficacy_of_continuous_terlipressin.7.aspx
22. Print Article | Cleveland Clinic Journal of medicine — www.ccjm.org — https://www.ccjm.org/custom-print/80137
23. Renal Effects of Angiotensin‐Converting Enzyme Inhibitors ... — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=
24. Diagnosis and management of ascites, spontaneous ... — www.ccjm.org — https://www.ccjm.org/content/90/4/209

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.